While their makers fight lawsuits and regulators keep watch on safety questions, the U.K.'s cost-effectiveness gatekeepers figure the new generation of anticoagulants should be used more to fight stroke, not less.
written on 18.06.2014
NICE backs thousands more scripts for clot-fighters Pradaxa, Xarelto, and Eliquis
